Mouse models of amyotrophic lateral sclerosis

Drug Discovery Today: Disease Models

Volumn 3, Issue 4, 2006, Pages 331-339

  Julien, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CEFTRIAXONE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; LYSINE ACETYLSALICYLATE; MICROTUBULE PROTEIN; MINOCYCLINE; NIMODIPINE; PROTEASOME; PROTEIN ALS2; RECOMBINANT ENZYME; RECOMBINANT VASCULOTROPIN; RILUZOLE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; CATALYSIS; CYTOSKELETON; DISEASE MODEL; DRUG POTENTIATION; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; GENETIC CODE; HUMAN; IMMUNIZATION; INTERMEDIATE FILAMENT; MISSENSE MUTATION; MITOCHONDRION; MOTOR NEURON DISEASE; NEUROFILAMENT; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN TRANSPORT; REVIEW; RNA INTERFERENCE; STEADY STATE; TRANSGENIC MOUSE; VIRAL GENE THERAPY;

EID: 33846597946     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2006.12.003     Document Type: Review

References (76)

1. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
2. Yang Y., et al. The gene encoding alsin, a protein with three guaninenucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29 (2001) 160-165
3. Hadano S., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29 (2001) 166-173
4. Eymard-Pierre E., et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the Alsin gene. Am. J. Hum. Genet. 71 (2002) 518-527
5. Puls I., et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33 (2003) 455-456
6. Chen Y.Z., et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74 (2004) 1128-1135
7. Nishimura A.L., et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75 (2004) 822-831
8. Lambrechts D., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
9. Van Vught P.W., et al. Lack of association between VEGF polymorphisms and ALS in a Dutch population. Neurology 65 (2005) 1643-1645
10. Greenway M.J., et al. A novel candidate region for ALS on chromosome 14q11.2. Neurology 63 (2004) 1936-1938
11. Hirano A., et al. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43 (1984) 471-480
12. Corbo M., and Hays A.P. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J. Neuropathol. Exp. Neurol. 51 (1992) 531-537
13. Pasinelli P., and Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7 (2006) 710-723
14. Reaume A.B., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13 (1996) 43-47
15. Cleveland D.W. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24 (1999) 515-520
16. Wiedau-Pazos M., et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271 (1996) 515-518
17. Beckman J.S., et al. ALS, SOD and peroxynitrite. Nature 364 (1993) 584
18. Subramaniam J.R., et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. 5 (2002) 301-307
19. Wang J., et al. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 10 (2002) 128-138
20. Jonsson P.A., et al. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 129 (2005) 451-464
21. Wang J., et al. Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: αB-crystallin modulates aggregation. Hum. Mol. Genet. 14 (2005) 2335-2347
22. Bruijn L.I., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18 (1997) 327-338
23. Bruijn L.I., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281 (1998) 1851-1854
24. Durham H.D., et al. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 56 (1997) 52-56
25. Johnston J.F., et al. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U S A 97 (2000) 12571-12576
26. Batulan Z., et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J. Neurosci. 23 (2003) 5789-5798
27. Urushitani M., et al. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 83 (2002) 1030-1042
28. Liu J., et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron (2004) 435-517
29. Pasinelli P., et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43 (2004) 19-30
30. Raoul C., et al. Motoneuron death triggered by a specific pathway downstream of Fas potentiation by ALS-linked SOD1 mutations. Neuron 35 (2002) 1067-1083
31. Bergemalm, et al. Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. J. Neurosci. 26 (2006) 4147-4154
32. Deng, et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. U S A 103 (2006) 7142-7147
33. Urushitani M., et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 9 (2006) 108-118
34. Kikuchi H., et al. Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc. Natl. Acad. Sci. U S A 103 (2006) 6025-6030
35. Clement A.M., et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 (2003) 113-117
36. Boillée S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 (2006) 1389-1392
37. Gowing G., et al. Absence of TNF-alpha does not affect motor neuron disease caused by SOD1 mutations. J. Neurosci. 26 (2006) 11397-11402
38. Millecamps S., et al. Defective axonal transport of neurofilament proteins in neurons overexpressing peripherin. J. Neurochem. 98 (2006) 926-938
39. Cai H., et al. Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J. Neurosci. 25 (2005) 7567-7574
40. Hadano S., et al. Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking. Hum. Mol. Genet. 15 (2006) 233-250
41. Devon R.S., et al. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc. Natl. Acad. Sci. U S A 103 (2006) 9595-9600
42. Yamanaka K., et al. Progressive spinal axonal degeneration and slowness in ALS2-deficient mice. Ann. Neurol. 60 (2006) 95-104
43. Julien J.-P., and Kriz J. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta (2006) 10.1016/jbbadis.2006.03.006
44. Zhao C., et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 105 (2001) 587-597
45. Xia C.H., et al. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J. Cell Biol. 161 (2003) 55-66
46. LaMonte B.H., et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34 (2002) 715-727
47. Hafezparast M., et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300 (2003) 808-812
48. Dairin K., et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 169 (2005) 561-567
49. Bommel H., et al. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J. Cell Biol. 159 (2002) 563-569
50. Martin N., et al. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat. Genet. 32 (2002) 443-447
51. Oosthuyse B., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28 (2001) 131-138
52. Gurney M.E., et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
53. Gurney M.E., et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50 (1998) 62-66
54. Barneoud P., and Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. 155 (1999) 243-251
55. Kriz J., et al. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10 (2002) 268-278
56. Zhu S., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
57. Van Den Bosch L., et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13 (2002) 1067-1070
58. Kriz J., et al. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53 (2003) 429-436
59. Rothstein J.D., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 (2005) 73-77
60. Crow J.P., et al. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 58 (2005) 258-265
61. Storkebaum E., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosc. 8 (2004) 85-92
62. Wang L.J., et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22 (2002) 6920-6928
63. Kaspar B.K., et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
64. Azzouz M., et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
65. Ralph G.S., et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11 (2005) 429-433
66. Raoul C., et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11 (2005) 423-428
67. Miller T.M., et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57 (2005) 773-776
68. Urushitani, M. et al. (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of ALS. Proc. Natl. Acad. Sci. USA, in press.
69. Klivenyi P., et al. Neuroprotective effects of creatin in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
70. Groeneveld G.J., et al. A randomized sequential trial of creatine monohydrate in amyotrophic lateral sclerosis. Ann. Neurol. 53 (2003) 437-445
71. Drachman D.B., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
72. Cudkowicz M.E., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 60 (2006) 22-31
73. Deshpande D.M., et al. Recovery from paralysis in adult rats using embryonic stem cells. Ann. Neurol. 60 (2006) 32-44
74. Côté F., et al. Progressive Neuronopathy in Transgenic Mice Expressing the Human Heavy Neurofilament (NFH) Gene: A Mouse Model of Amyotrophic Lateral Sclerosis. Cell 73 (1993) 35-46
75. Lee M.K., et al. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 13 (1994) 975-988
76. Nguyen M.D., et al. Deregulation of Cdk5 in a mouse model of ALS: Toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30 (2001) 135-147